These Are The Hottest Biotech Startups In France!

20 Hottest Biotech Startups In France!

  

French biotech ecosystem is one of the leading industry in Europe along with UK & Germany. The country has revolutionized the biotech sector by incubating some exciting startups in this space. In 2017 the revenues of biotechnology R&D in France was nearly $3B.

 


 

French biotech startups has attracted many global investors in 2017. And some of their startups has already received funding in 2018, including Enterome, Gecko, HalioDx Etc.

  

Here Are The 20 Hottest Biotech Startups In France:

  

1. Enterome:

 

 

Year Founded: 2012

Enterome is a clinical stage company, pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases. The company develops science-based personalized medical tests and companion diagnostics based on profiling of the human gut microbiome with the goal to improve management of microbiome-related diseases, e.g., metabolic, gastrointestinal, and autoimmune.

Total Funding: €101.5M in 5 funding rounds
Last Funding Type: Series D, on Jan 4, 2018


Lead Investors: Seventure Partners, European Investment Bank (EIB) & Lundbeckfonden Ventures

  

2. GenSight Biologics:

 

 

Year Founded: 2013

A clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases.

Total Funding: $102.8M in 3 funding rounds
Last Funding Type: Post IPO Equity, on Jun 23, 2017


Lead Investors: Index Ventures, Versant Ventures, Novartis Venture Fund & Abingworth

  

3. ERYtech:

 

 

Year Founded: 2004

A biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.

Total Funding: €92.2M in 7 funding rounds
Last Funding Type: Post-IPO Equity, Dec 7, 2015
Valuation At IPO: $398M


Investors: Auriga Partners, Ardian, Idinvest Partners, CapDecisif Management & Amorçage Rhône Alpes

  

4. Gecko Biomedical:

 

 

Year Founded: 2013

A privately owned life science company developing innovative polymer solutions for Tissue Reconstruction. Gecko has developed a fully industrialised platform allowing the swift development of proprietary medical devices around its polymer families.

Total Funding: €39.2M in 5 funding rounds
Last Funding Type: Grant, on Jan 24, 2018


Lead Investors: Bpifrance, Sofinnova Partners, Omnes Capital & CM-CIC Capital Finance

  

5. Medday:

 

 

Year Founded: 2011

A biotechnology company that develops new drugs for neurological and psychiatric diseases. MedDay provides MD1003, a solution for the treatment of primary and secondary progressive multiple sclerosis; MD1103, a solution for autism spectrum disorders; and MD1105, a solution for Alzheimer’s disease.

Total Funding: $49M in 2 funding rounds
Last Funding Type: Series B, on Apr 8, 2016


Lead Investors: Edmond de Rothschild Investment Partners & Sofinnova Partners

  

6. Horama:

 

 

Year Founded: 2014

A clinical-stage biopharmaceutical company developing gene therapy therapies based on vectors derived from a recombinant adeno-associated virus (rAAV) targeting rare diseases of the retina. Horama focuses on the development of gene therapy products to rare ophthalmology pathologies with recombinant adeno-associated viral vectors for orphan blinding diseases.

Total Funding: €23M in 2 funding rounds
Last Funding Type: Series B, on Nov 8, 2017


Lead Investor: Kurma Partners

  

7. Prophesee:

 

 

Year Founded: 2014

A provider of bio-inspired computer vision solutions for autonomous navigation and connected objects. Prophesee develops innovative machine vision sensors and systems for applications in all fields of machine vision. The sensor technology is inspired by biological eyes, acquiring and processing the visual information in an extremely performing yet highly efficient way.

Total Funding: $37.3M in 4 funding rounds
Last Funding Type: Series B, on Feb 21, 2018


Lead Investors: Intel Capital & Robert Bosch Venture Capital

  

8. Eligo Biosciences:

 

 

Year Founded: 2014

Eligo Bioscience is a young biotech that develops smart antibiotics for microbiome precision-editing. It provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals.

Total Funding: $22.9M in 3 funding rounds
Last Funding Type: Series A, on Sep 26, 2017


Lead Investors: Seventure Partners, Khosla Ventures & Worldwide Innovation Challenge

  

9. HalioDx:

 

 

Year Founded: 2015

An immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. HalioDx Immunoscore® technology integrates immunohistochemistry combined with advanced imaging analysis enabling extraction of spatially-organized tissue molecular information.

Total Funding: €26.5M in 2 funding rounds
Last Funding Type: Series B, on Jan 17, 2018


Investors: Quest for Growth, BNP Paribas Développement & MI Care Etc.

  

10. Onxeo:

 

 

Year Founded: 1997

A biotechnology company that designs and develops innovative medicines for the treatment of cancer and its associated pathologies, more specifically for severe or rare diseases with orphan status. Onxeo is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Total Funding: €15M 1 funding round
Last Funding Type: Post-IPO Equity


Acquisition: Acquired DNA Therapeutics on Feb 29, 2016 for $1.9M

  

11. Pherecydes Pharma:

 

 

Year Founded: 2006

A pharmaceutical company that engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. Pherecydes Pharma develops several banks of bacteriophages, including the collection of phages against Escherichia coli.

Total Funding: €10.6M in 2 funding rounds
Last Funding Type: Series B, Jan 16, 2018


Lead Investors: GO CAPITAL

  

12. Nanobiotix:

 

 

Year Founded: 2003

A nano medicine company developing novel therapeutics for the local treatment of cancer. Nanobiotix provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Total Funding: $14.6M in 2 funding rounds
Last Funding Type: Jul 4, 2013


Investors: Bpifrance, Amorçage Rhône Alpes, CIC Vizille Capital Innovation, CapDecisif Management, Seventure Partners & OTC Asset Management

  

13. OSE Immunotherapeutics:

 

 

Year Founded: 2012

OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation.

Total Funding: €10.3M in 1 funding round
Last Funding Type: Post-IPO Equity, Dec 28, 2016


Acquisition: Acquired Effimune SAS on Feb 24, 2016

  

14. ENYO Pharma:

 

 

Year Founded: 2014

A privately held biopharmaceutical company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. ENYO Pharma develops new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology.

Total Funding: €24.5M in 2 funding rounds
Last Funding Type: Grant, on Dec 6, 2016


Lead Investor: Sofinnova Partners

  

15. Ynsect:

 

 

Year Founded: 2011

A biotech company that designs, builds, and operates insect production and processing facilities for the production of feed for fish and poultry. Ynsect’s main activities include the bioconversion of organic resources by insects, and their processing into nutrients for feed applications (proteins, lipids, and others) and non-food applications (polysaccharides and derivatives, organic fertilizers, bioenergy, and others).

Total Funding: $24.5M in 3 funding rounds
Last Funding Type: Series B, on Dec 14, 2016


Lead Investors: Future Positive Capital & Bpifrance

  

16. THERAVECTYS:

 

 

Year Founded: 2005

A privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs.

Total Funding: €24.1M in 3 funding rounds
Last Funding: Grant, Jan 26, 2015


Lead Investor: Tethys BioScience

  

17. Graftys:

 

 

Year Founded: 2005

An early-stage company that is focused on advanced bone biologics. Graftys develops, manufactures and markets synthetic bioactive orthopedic biomaterials. The company’s technologies provide innovative therapeutic products in bone tissue engineering for unmet medical needs.

Total Funding: €5.3M in 1 funding round
Funding Type: Series C, on Apr 26, 2011


Investors: Ventech, Oreo Finances, Octalfa & ACG Management

  

18. LYSOGENE:

 

 

Year Founded: 2009

A pioneering biotechnology company in the field of gene therapy targeting severe genetic pathologies of the central nervous system in children. LYSOGENE is the only biotechnology company in the world that is specialised in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.

Total Funding: $22M in 1 funding round
Funding Type: Series A, on May 21, 2014


Lead Investor: Sofinnova Ventures

  

19. Global Bioenergies:

 

 

Year Founded: 2008

A biotech company that is developing a process to convert renewable resources into hydrocarbons through fermentation. Global Bioenergies was initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers.

Total Funding: $23M in 1 funding round
Funding Type: Private Equity Round, on Jul 17, 2013
Investors: CM-CIC Capital Prive & Seventure Partners


Acquisition: Acquired Syngip B.V. on Dec 21, 2016

  

20. DBV Technologies:

 

 

Year Founded: 2002

A global biopharmaceutical company dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV Technologies is known for developing “Viaskin” technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood.

Total Funding: $51.1M in 4 funding rounds
Last Funding Type: Series C, on Jan 5, 2011


Lead Investors: Lundbeckfonden Ventures, InnoBio Fund & Sofinnova Partners

   

Leave a Reply